Epidarex is honored to have Elizabeth Roper, Partner, selected as one of the 50 Movers and Shakers in BioBusiness for 2016 from the Cambridge, UK-based
Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr.
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the
Business Quarter interviews Sinclair Dunlop, Managing Partner of Epidarex Capital on venture capital, innovation, and the funding gap in Scotland. Click here for a link
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2.
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding